Omaveloxolone (RTA-408, Skyclarys™) is a synthetic triterpenoid that acts as a potent activator of Nrf2 (NF-E2-related factor 2), a transcription factor regulating antioxidant and cytoprotective responses. This mechanism reduces oxidative stress, mitochondrial dysfunction, and inflammation. It received FDA approval in February 2023 as Skyclarys for treating Friedreich's ataxia (FA) in patients aged 16 years and older, a genetic mitochondrial disease causing progressive neurodegeneration and movement disorders. Ongoing research and clinical trials explore its potential in other neurodegenerative diseases (e.g., ALS, Parkinson's), mitochondrial disorders, and inflammatory conditions like NASH. Offered as a high-purity (≥99%) research reagent for laboratory use.